Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Sibbing

Showing results (51-60 of 200) with videos related to

Pageof 20
Sort By:
Circulation. Cardiovascular Interventions|October 20, 2011
Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stentingDirk Sibbing, Isabell Bernlochner, Adnan Kastrati, et al.
Circulation. Cardiovascular Interventions|October 20, 2011
Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary interventionGuillaume Paré, John W Eikelboom, Dirk Sibbing, et al.
Journal of the American College of Cardiology|July 17, 2010
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic windowDirk Sibbing, Steven R Steinhubl, Stefanie Schulz, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 3, 2007
Platelet function in clopidogrel-treated patients with acute coronary syndromeDirk Sibbing, Olga von Beckerath, Albert Schömig, et al.
The American Journal of Cardiology|July 17, 2007
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary interventionDirk Sibbing, Olga von Beckerath, Albert Schömig, et al.
Interventional Cardiology Clinics|December 14, 2024
Switching Platelet P2Y<sub>12</sub> Receptor Inhibiting TherapiesLuis Ortega-Paz, Fabiana Rollini, Francesco Franchi, et al.
Thrombosis and Haemostasis|July 5, 2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shockMartin Orban, Robert A Byrne, Jörg Hausleiter, et al.
Expert Review of Cardiovascular Therapy|May 13, 2025
Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromesDirk Sibbing, Augusto María Lavalle Cobo, Zhongwei Shi, et al.
American Journal of Preventive Cardiology|May 2, 2024
Needs-based considerations for the role of low-dose aspirin along the CV risk continuumFrancesca Santilli, Gerhard Albrecht, Michael Blaha, et al.
Journal of the American College of Cardiology|March 26, 2013
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulationNikolaus Sarafoff, Amadea Martischnig, Jill Wealer, et al.
Pageof 20

Showing results (51-60 of 200) with videos related to

Sort By:
Pageof 20
Circulation. Cardiovascular Interventions|October 20, 2011
Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stentingDirk Sibbing, Isabell Bernlochner, Adnan Kastrati, et al.
Circulation. Cardiovascular Interventions|October 20, 2011
Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary interventionGuillaume Paré, John W Eikelboom, Dirk Sibbing, et al.
Journal of the American College of Cardiology|July 17, 2010
Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic windowDirk Sibbing, Steven R Steinhubl, Stefanie Schulz, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|May 3, 2007
Platelet function in clopidogrel-treated patients with acute coronary syndromeDirk Sibbing, Olga von Beckerath, Albert Schömig, et al.
The American Journal of Cardiology|July 17, 2007
Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary interventionDirk Sibbing, Olga von Beckerath, Albert Schömig, et al.
Interventional Cardiology Clinics|December 14, 2024
Switching Platelet P2Y<sub>12</sub> Receptor Inhibiting TherapiesLuis Ortega-Paz, Fabiana Rollini, Francesco Franchi, et al.
Thrombosis and Haemostasis|July 5, 2011
Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shockMartin Orban, Robert A Byrne, Jörg Hausleiter, et al.
Expert Review of Cardiovascular Therapy|May 13, 2025
Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromesDirk Sibbing, Augusto María Lavalle Cobo, Zhongwei Shi, et al.
American Journal of Preventive Cardiology|May 2, 2024
Needs-based considerations for the role of low-dose aspirin along the CV risk continuumFrancesca Santilli, Gerhard Albrecht, Michael Blaha, et al.
Journal of the American College of Cardiology|March 26, 2013
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulationNikolaus Sarafoff, Amadea Martischnig, Jill Wealer, et al.
Pageof 20